News | November 10, 2021
Moderna seeks approval from EMA for its Covid-19 vaccine for children between 6-11 years
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
The submission is based on Phase 2/3 study of mRNA-1273 in children ages 6 to 11
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
In participants 5 to 11 years of age, the vaccine was safe, well-tolerated and showed robust neutralising antibody responses. Results in children under 5 years of age are expected as soon as later this year
It has been built at a cost of Rs 19.5 crores through internal accruals of the Malabar Institute of Medical Sciences (MIMS)
Laurus will be incentivised for a portion of its development and commercialisation costs. CHAI will also provide technical and regulatory support to enable accelerated generic development
The trial will be conducted across 10 sites in India
Seen in 1 in 3 million births, the malformation was detected at the antenatal stage during the mother's pregnancy
The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer
The director of Apollo Cancer Centres in Hyderabad and founder of CURE Foundation honored for his contributions to cancer awareness and treatment
If cleared, MAVIRET would become one of the few therapies in the European Union approved to treat both acute and chronic hepatitis C infections
Subscribe To Our Newsletter & Stay Updated
